Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes    Leukemias    Solid Tumors    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
    

Voltage-Gated Sodium Channel expression and cancer

 

Zehua Wang

Prof. and Chief of Department of Obstetrics and Gynecology,
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology,
Wuhan, 430022 China

 

May 2011

 

 

Ion channels are pore-forming proteins and their function is to facilitate the diffusion of ion across cell membranes by flow of ions down the electrochemical gradient. Voltage-gated ion channels are a class of transmembrane ion channels and are found throughout the body which allowed a rapid and coordinated depolarization in response to voltage change in excitable cells (Catterall, 2010). Recent studies have demonstrated that Voltage-gated ion channels had been found in non-excitable cells. Among these channels, Voltage-gated sodium channels (VGSC) are the new topic and increasing evidences have suggested that which participated in the oncogenic process (Fiske et al., 2006; Mechaly et al., 2005).

1. VGSC subunits and structure

VGSC is a large transmembrane glycoprotein complexes, composed of a highly processed α subunits (VGSCαs) with 24 transmembrane domains and one or more regulatory β subunits (VGSCβs), which mediate the all-or-none action potential initiation and propagation in excitable cells and tissues. When VGSC is activated, influx of sodium ions through channel depolarizes the cell membrane and initiates the rising phase of the action potential (Catterall, 2000).
VGSCαs are approximately 260 kDa, which have been identified ten encoding genes up to now. According to the phylogeny difference, Nav1.1 to Nav1.9 of nine isoforms constitute the functional subunits of VGSCαs and name Nav1 family, there are greater than 50% identical in amino acid sequence in these structure. As for another isoform Nax, its structure and function are different with Nav1 family and which seem to be regulated by sodium concentration but not by voltage. In case of Nav1 family, each isform is made up of a single polypeptide with 4 homologous domains (D1-D4) and every domain has 6 transmembrane segments (S1-S6). There are several functional parts about Nav1 structure. Among them, the S4 serves as a voltage sensor, which responds to the levels of the membrane potential, the S5/S6 pore-forming regions determine its ion selectivity, which is quite selective for sodium ions (Goldin et al., 2000; Goldin, 2001). Tetrodotoxin (TTX) is a potent neurotoxin, which blocks action potentials by binding to the VGSC in cell membranes. The binding site of TTX is located at the pore opening of VGSC (Narahashi, 2008). According to the sensitivity to TTX, Nav1 family was described as TTX-sensitive (TTX-S; Nav1.1-1.4, Nav1.6-1.7) and TTX-resistant (TTX-R; Nav1.5, Nav1.8, Nav1.9).
VGSCβs are approximately 30-40 kDa, which have been found that modified the channel and current density, kinetics and voltage-dependence of gating. To date, β1 to β4 of four isoforms encoded by SCN1B to SCN4B have been defined and they were the transmembrane proteins which contain a similar structure, consisting of one N-terminal extracellular immunoglobulin domain, one transmembrane segment, and a small intracellular domain (Brackenbury and Isom, 2008).

2. VGSCαs and cancer

With the development of patch clamp technique and molecular biology, the functional expressions of VGSCαs have been reported in cancer cells (Palmer et al., 2008). The group of Mustafa Djamgoz in England first found the sodium current in highly metastatic rat prostate cancer cell line Mat-Ly-Lu using patch clamp technique, but not in the weakly metastatic counterparts of AT-2 cells (Grimes et al., 1995). Over the past few years, researchers have described that inhibiting the activity of VGSCαs could significantly reduce the invasion of the highly metastatic cancer cells but without obvious effect on weakly metastatic cancer cells (Roger et al., 2007; Gao et al., 2010; Diaz et al., 2007). At present, the group of Mustafa Djamgoz in England and the group of Le Guennec in France have made the best understood about VGSCαs and cancer (Roger et al., 2006). In this section, we would summarize the functional expression of VGSC Nav1.5 and Nav1.7 in cancer cells.

2. 1 The functional expression of Nav1.5 in cancer cells

Individual VGSCαs subtypes can generate unique physiological signatures in different cell types and generate multiple expressions of individual VGSCαs subtypes in single cells (Diss et al., 2004). During recent years, increasing evidence has been accumulated in supporting that Nav1.5 can cause a variety of pathophysiological phenotypes in cancer cells (Schroeter et al., 2010). As we have known, Nav1.5 is belonging to the TTX-R isoform and encoded by the SCN5A gene, which is normally associated with human cardiac tissue and located on chromosome 3p21-24. It plays important roles in the excitability of atrial and ventricular cardiomyocytes and in rapid impulse propagation (Schroeter et al., 2010).
In 2003, the group of Le Guennec in France reported that VGSCαs were expressed in a highly metastatic breast cancer cell MDA-MB-231 but was not detected in the weakly metastatic MCF-7 cells (Roger et al., 2003). Later on, the group of Mustafa Djamgoz in England further found that the mainly isoform expressed in breast cancer highly metastatic cells was the Nav1.5, and inhibition of Nav1.5 with TTX could markedly reduced the invasion of MDA-MB-231 cells (Fraser et al., 2005). Interestingly, our research also demonstrated that the abnormal expression of Nav1.5 could be an integral component of the metastatic process in human ovarian cancer and inhibiting the activity of Nav1.5 could significant reduce the invasion of cancer cells (Gao et al., 2010). In addition, many similar discovery have also been reported a predominant expression of Nav1.5 in colon cancer and T-lymphocyte Jurkat cells (House et al., 2010; Fraser et al., 2004).
Alternative splicing are sophisticated and ubiquitous nuclear process, they are important in normal development by creating protein diversity in complex organisms and also are natural source of cancer-causing errors in gene expression (Venables, 2004). Up to now, six Nav1.5 splice variants have been reported in Gene Bank (NM_000335.4; NM_001099404.1; NM_001099405.1; NM_001160160.1; NM_001160161.1; NM_198056.2). To date, Diss et al. and Schroeter et al. subsequently summarized the currently known functional splice variants of Nav1.5, they both mentioned the naturally occurring Nav1.5 splice variants (Diss et al., 2004; Schroeter et al., 2010). Among these splice variants, the D1:S3 3' splice variant and D1:S3 5' splice variant are the predominant, which can lead to multiple 5'- and 3'-noncoding regions, resulting in the mutations of SCN5A. Because D1:S3 5' splice variant differs from D1:S3 3' splice variant at 31 nucleotides and result in 7 amino acid substitutions (Fraser et al., 2005), Brackenbury et al. designed the siRNA and a polyclonal antibody of targeting D1:S3 5' splice variant, which could rapidly reduce the activity of Nav1.5 and the invasion of MDA-MB-231 cells (Brackenbury et al., 2007). Further research has also shown that the D1:S3 5' splice variant were expressed in cancer cells, the expression levels of different Nav1.5 splice variants were diversity at different stage of development, the D1:S3 3' splice variant gradually increased during the developing of organism, while D1:S3 5' splice variant was decreased significantly in the mature cells even though which is abundant at embryonic stage (Zimmer et al., 2002). However, House et al. recently found that the functional isoforms in colon cancer was the D1:S3 3' splice of Nav1.5 but not the D1:S3 5' correspondence (House et al., 2010). In this study, researchers presumed that the recruitment of Nav1.5 expression might facilitate the regulation of a colon cancer invasion network involving downstream genes which encompass the Wnt signaling way.
Until now, the exact mechanisms by which different Nav1.5 splice variants functional expressed in different cancer cells remain unknown. Pan et al. reported that biochemical constitution of extracellular medium was critical in control of MDA-MB-231 cell motility (Pan and Djamgoz, 2009). Nav1.5 involving in the metastasis might have an indirect effect through the regulation of intracellular sodium homeostasis, the influx of Na+ could alter the release or uptake of Ca2+ from intracellular stores by deregulation of intracellular H+ concentration. Gillet et al. propose that Nav1.5 enhance the invasiveness of MDA-MB-231 cells by favoring the pH-dependent activity of cysteine cathepsins (Gillet et al., 2009). Subsequently, Brisson et al. demonstrated that Nav1.5 could enhance MDA-MB-231 cells invasiveness by increasing Na+/H+ exchanger type 1-dependent H+ efflux (Brisson et al., 2011). Furthermore, the rise influx of Na+ could also activate protein kinase A (PKA), which could lead to phosphorylation of cytoskeletal components. Chioni et al. also founded that PKA plays an important role in functional expression of Nav1.5 in MDA-MB-231 cells by mediating activity-dependent positive feedback, and which enhances the metastatic of MDA-MB-231 cells in turn (Chioni et al., 2010). Therefore, this general mechanism could lead to the identification of new targets allowing the therapeutic prevention of metastases.

2. 2 The functional expression of Nav1.7 in cancer

Nav1.4 was first found functionally expressed in rat and human prostate cancer cell lines other than skeletal muscle in 1995. In this paper, the author reported that Nav1.4 is not only present in the highly metastatic MAT-LyLu and PC-3 cells, but also was detected in the weakly metastatic AT-2 and LNCaP cells (Diss et al., 1998). Interestingly, Bennett et al. reported that when Nav1.4 was transiently expressed in non-metastatic LNCaP cell, its invasion was sharply increased and the increased invasion could be completely reversed by treatment with TTX (Bennett et al., 2004). However, further research revealed that main isoform functionally expressed in prostate cancer was NaV1.7 but not Nav1.4, and researcher concluded that the NaV1.4 expressed in weakly metastatic cells might be at a sub-threshold density (Roger et al., 2006; Bennett et al., 2004).
As we have known, the TTX-S isoform Nav1.4 is encoded by SCN4A gene and located on chromosome 2, it is responsible for the generation and propagation of action potentials in neurons and muscle and broadly expressed in skeletal muscle (Jurkat-Rott et al., 2010). While the TTX-S isoform Nav1.7 is encoded by SCN9A gene and located on chromosome 2q23-24, it is necessary for pain sensation and broadly expressed in neurons (Wood et al., 2004). Recently research have shown that loss of function of Nav1.7 could cause a congenital inability to experience pain in humans, while gain of function of Nav1.7 could enhance the invasion of rat and human prostate cancer cells (Fischer and Waxman, 2010).
In 2001, Diss et al. reported that the main mRNA isoform expressed in Mat-Ly-Lu and PC3 cells was NaV1.7 (Diss et al., 2001). Later on, the same research group reported that the functional expression of NaV1.7 was related with the development of prostate cancer, NaV1.7 might be a potential novel marker for human prostate cancer (Diss et al., 2005). Over the past few years, NaV1.7 also been reported that participated in the invasion in human non-small-cell lung cancer cells, cervical cancer cells and so on (Roger et al., 2007; Diaz et al., 2007; Roger et al., 2006).
However, the mechanisms responsible for the functional expression of NaV1.7 in metastatic cancer cells also remain unknown. Growth factors have been shown to play the important roles in regulation of Nav1.7 transcription in prostate cancer strongly metastatic cells (Uysal-Onganer and Djamgoz, 2007; Ding et al., 2008). The expressions of Nav1.7 were under auto-regulation by activity-dependent positive feed-back which dominated the effect of different growth factors and which might be made effect on by PKA activation. In addition, over expressions of Nav1.7 also induced Ca2+ influx led to protein kinase C α (PKCα) phosphorylation and glycogen synthase kinase-3β (GSK-3β) phosphorylation by activating activated ERK1/ERK2 and p38 pathway (Kanai et al., 2009).

3. VGSCβs and cancer

Due to VGSCβs subunits are multi-functional molecules, they are homologous to the immunoglobulin superfamily of cell adhesion molecules (CAMs) and play important roles in regulating cellular excitability, adhesion and metastatic activity in cancer (Isom, 2001). So far, the study of VGSCβs and cancer was mainly in breast cancer and prostate cancer cells. The group of Mustafa Djamgoz in London first found VGSCβs were expressed in prostate cancer cells and reducing the expression of β1 or disturbing its association with Nav1.7 could significantly reducing metastatic cell behaviour (Diss et al., 2008). In 2008, the same group further shown that the expression levels of β1 were significantly higher in weakly metastatic MCF-7 cells than strongly metastatic MDA-MB-231 cells, and silencing SCN1B using siRNA could increase the migration of MCF-7 cells, which suggested that β1 might as a novel cell adhesion molecule control the expression levels of Nav1.5 and cellular migration in breast cancer cells (Chioni et al., 2009). Therefore, it is inferred that VGSCβs might be involved in VGSCαs intracellular trafficking and functional expression by protein-protein interactions may, and the co-expression of VGSCβs and VGSCαs might increase the current density and the efficiency with which the mature channel protein was targeted to plasma membrane (Johnson and Bennett, 2006).

4. Conclusions

In conclusion, VGSC expressions were functionally up-regulated in many cancer cells by involving in transcriptional, pre-translational, translational, post-translational regulation (Shao et al., 2009). In addition, recent studies have reported that using of local anesthetics (the blockers of VGSC) during surgical resection of cancers was associated with a reduced risk of clinical cancer reoccurrence and metastasis (Wuethrich et al., 2010). Therefore, it should be noted that in the future studies that how VGSC activity participate in the progress of cancer, and VGSC functional expression in cancer cells might represent a novel mechanism for potentiating cellular metastasis and promising a new therapeutic strategy against cancers.

Bibliography

Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro.
Grimes JA, Fraser SP, Stephens GJ, Downing JE, Laniado ME, Foster CS, Abel PD, Djamgoz MB.
FEBS Lett. 1995 Aug 7;369(2-3):290-4.
PMID 7649275
 
Expression of skeletal muscle-type voltage-gated Na+ channel in rat and human prostate cancer cell lines.
Diss JK, Stewart D, Fraser SP, Black JA, Dib-Hajj S, Waxman SG, Archer SN, Djamgoz MB.
FEBS Lett. 1998 May 1;427(1):5-10.
PMID 9613589
 
From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels.
Catterall WA.
Neuron. 2000 Apr;26(1):13-25. (REVIEW)
PMID 10798388
 
Nomenclature of voltage-gated sodium channels.
Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC, Kallen RG, Mandel G, Meisler MH, Netter YB, Noda M, Tamkun MM, Waxman SG, Wood JN, Catterall WA.
Neuron. 2000 Nov;28(2):365-8.
PMID 11144347
 
Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines.
Diss JK, Archer SN, Hirano J, Fraser SP, Djamgoz MB.
Prostate. 2001 Aug 1;48(3):165-78.
PMID 11494332
 
Resurgence of sodium channel research.
Goldin AL.
Annu Rev Physiol. 2001;63:871-94.
PMID 11181979
 
Sodium channel beta subunits: anything but auxiliary.
Isom LL.
Neuroscientist. 2001 Feb;7(1):42-54. (REVIEW)
PMID 11486343
 
Mouse heart Na+ channels: primary structure and function of two isoforms and alternatively spliced variants.
Zimmer T, Bollensdorff C, Haufe V, Birch-Hirschfeld E, Benndorf K.
Am J Physiol Heart Circ Physiol. 2002 Mar;282(3):H1007-17.
PMID 11834499
 
Involvement of a novel fast inward sodium current in the invasion capacity of a breast cancer cell line.
Roger S, Besson P, Le Guennec JY.
Biochim Biophys Acta. 2003 Oct 13;1616(2):107-11.
PMID 14561467
 
Voltage-gated Na+ channels confer invasive properties on human prostate cancer cells.
Bennett ES, Smith BA, Harper JM.
Pflugers Arch. 2004 Mar;447(6):908-14. Epub 2003 Dec 16.
PMID 14677067
 
Voltage-gated Na+ channels: multiplicity of expression, plasticity, functional implications and pathophysiological aspects.
Diss JK, Fraser SP, Djamgoz MB.
Eur Biophys J. 2004 May;33(3):180-93. Epub 2004 Feb 12. (REVIEW)
PMID 14963621
 
T-lymphocyte invasiveness: control by voltage-gated Na+ channel activity.
Fraser SP, Diss JK, Lloyd LJ, Pani F, Chioni AM, George AJ, Djamgoz MB.
FEBS Lett. 2004 Jul 2;569(1-3):191-4.
PMID 15225632
 
Aberrant and alternative splicing in cancer.
Venables JP.
Cancer Res. 2004 Nov 1;64(21):7647-54. (REVIEW)
PMID 15520162
 
Voltage-gated sodium channels and pain pathways.
Wood JN, Boorman JP, Okuse K, Baker MD.
J Neurobiol. 2004 Oct;61(1):55-71. (REVIEW)
PMID 15362153
 
A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo.
Diss JK, Stewart D, Pani F, Foster CS, Walker MM, Patel A, Djamgoz MB.
Prostate Cancer Prostatic Dis. 2005;8(3):266-73.
PMID 16088330
 
Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis.
Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, Brackenbury WJ, Theodorou D, Koyutürk M, Kaya H, Battaloglu E, De Bella MT, Slade MJ, Tolhurst R, Palmieri C, Jiang J, Latchman DS, Coombes RC, Djamgoz MB.
Clin Cancer Res. 2005 Aug 1;11(15):5381-9.
PMID 16061851
 
Molecular diversity of voltage-gated sodium channel alpha subunits expressed in neuronal and non-neuronal excitable cells.
Mechaly I, Scamps F, Chabbert C, Sans A, Valmier J.
Neuroscience. 2005;130(2):389-96.
PMID 15664695
 
Voltage-sensitive ion channels and cancer.
Fiske JL, Fomin VP, Brown ML, Duncan RL, Sikes RA.
Cancer Metastasis Rev. 2006 Sep;25(3):493-500. (REVIEW)
PMID 17111226
 
Isoform-specific effects of the beta2 subunit on voltage-gated sodium channel gating.
Johnson D, Bennett ES.
J Biol Chem. 2006 Sep 8;281(36):25875-81. Epub 2006 Jul 17.
PMID 16847056
 
Voltage-gated sodium channels: new targets in cancer therapy?
Roger S, Potier M, Vandier C, Besson P, Le Guennec JY.
Curr Pharm Des. 2006;12(28):3681-95. (REVIEW)
PMID 17073667
 
The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells.
Brackenbury WJ, Chioni AM, Diss JK, Djamgoz MB.
Breast Cancer Res Treat. 2007 Jan;101(2):149-60. Epub 2006 Jul 13.
PMID 16838113
 
Functional expression of voltage-gated sodium channels in primary cultures of human cervical cancer.
Diaz D, Delgadillo DM, Hernandez-Gallegos E, Ramirez-Dominguez ME, Hinojosa LM, Ortiz CS, Berumen J, Camacho J, Gomora JC.
J Cell Physiol. 2007 Feb;210(2):469-78.
PMID 17051596
 
Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines.
Roger S, Rollin J, Barascu A, Besson P, Raynal PI, Iochmann S, Lei M, Bougnoux P, Gruel Y, Le Guennec JY.
Int J Biochem Cell Biol. 2007;39(4):774-86. Epub 2007 Jan 20.
PMID 17307016
 
Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel.
Uysal-Onganer P, Djamgoz MB.
Mol Cancer. 2007 Nov 24;6:76.
PMID 18036246
 
Voltage-gated Na+ channels: potential for beta subunits as therapeutic targets.
Brackenbury WJ, Isom LL.
Expert Opin Ther Targets. 2008 Sep;12(9):1191-203.
PMID 18694383
 
Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity.
Ding Y, Brackenbury WJ, Onganer PU, Montano X, Porter LM, Bates LF, Djamgoz MB.
J Cell Physiol. 2008 Apr;215(1):77-81.
PMID 17960590
 
Identification and characterization of the promoter region of the Nav1.7 voltage-gated sodium channel gene (SCN9A).
Diss JK, Calissano M, Gascoyne D, Djamgoz MB, Latchman DS.
Mol Cell Neurosci. 2008 Mar;37(3):537-47. Epub 2007 Dec 15.
PMID 18249135
 
Tetrodotoxin: a brief history.
Narahashi T.
Proc Jpn Acad Ser B Phys Biol Sci. 2008;84(5):147-54. (REVIEW)
PMID 18941294
 
Single cell adhesion measuring apparatus (SCAMA): application to cancer cell lines of different metastatic potential and voltage-gated Na+ channel expression.
Palmer CP, Mycielska ME, Burcu H, Osman K, Collins T, Beckerman R, Perrett R, Johnson H, Aydar E, Djamgoz MB.
Eur Biophys J. 2008 Apr;37(4):359-68. Epub 2007 Sep 19.
PMID 17879092
 
A novel adhesion molecule in human breast cancer cells: voltage-gated Na+ channel beta1 subunit.
Chioni AM, Brackenbury WJ, Calhoun JD, Isom LL, Djamgoz MB.
Int J Biochem Cell Biol. 2009 May;41(5):1216-27. Epub 2008 Nov 12.
PMID 19041953
 
Voltage-gated Sodium Channel Activity Promotes Cysteine Cathepsin-dependent Invasiveness and Colony Growth of Human Cancer Cells.
Gillet L, Roger S, Besson P, Lecaille F, Gore J, Bougnoux P, Lalmanach G, Le Guennec JY.
J Biol Chem. 2009 Mar 27;284(13):8680-91. Epub 2009 Jan 28.
PMID 19176528
 
Nav1.7 sodium channel-induced Ca2+ influx decreases tau phosphorylation via glycogen synthase kinase-3beta in adrenal chromaffin cells.
Kanai T, Nemoto T, Yanagita T, Maruta T, Satoh S, Yoshikawa N, Wada A.
Neurochem Int. 2009 Jul;54(8):497-505. Epub 2009 Feb 24.
PMID 19428794
 
Protein-protein interactions involving voltage-gated sodium channels: Post-translational regulation, intracellular trafficking and functional expression.
Shao D, Okuse K, Djamgoz MB.
Int J Biochem Cell Biol. 2009 Jul;41(7):1471-81. Epub 2009 Feb 2. (REVIEW)
PMID 19401147
 
Ion channel voltage sensors: structure, function, and pathophysiology.
Catterall WA.
Neuron. 2010 Sep 23;67(6):915-28. (REVIEW)
PMID 20869590
 
Protein kinase A and regulation of neonatal Nav1.5 expression in human breast cancer cells: activity-dependent positive feedback and cellular migration.
Chioni AM, Shao D, Grose R, Djamgoz MB.
Int J Biochem Cell Biol. 2010 Feb;42(2):346-58. Epub 2009 Dec 3.
PMID 19948241
 
Familial pain syndromes from mutations of the NaV1.7 sodium channel.
Fischer TZ, Waxman SG.
Ann N Y Acad Sci. 2010 Jan;1184:196-207. (REVIEW)
PMID 20146699
 
Expression of voltage-gated sodium channel alpha subunit in human ovarian cancer.
Gao R, Shen Y, Cai J, Lei M, Wang Z.
Oncol Rep. 2010 May;23(5):1293-9.
PMID 20372843
 
Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion.
House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, Sarvazyan N, Irby R, Strausberg RL, Hales TG, Stuart JM, Lee NH.
Cancer Res. 2010 Sep 1;70(17):6957-67. Epub 2010 Jul 22.
PMID 20651255
 
Sodium channelopathies of skeletal muscle result from gain or loss of function.
Jurkat-Rott K, Holzherr B, Fauler M, Lehmann-Horn F.
Pflugers Arch. 2010 Jul;460(2):239-48. Epub 2010 Mar 17. (REVIEW)
PMID 20237798
 
Structure and function of splice variants of the cardiac voltage-gated sodium channel Na(v)1.5.
Schroeter A, Walzik S, Blechschmidt S, Haufe V, Benndorf K, Zimmer T.
J Mol Cell Cardiol. 2010 Jul;49(1):16-24. Epub 2010 Apr 14. (REVIEW)
PMID 20398673
 
Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: a retrospective study.
Wuethrich PY, Hsu Schmitz SF, Kessler TM, Thalmann GN, Studer UE, Stueber F, Burkhard FC.
Anesthesiology. 2010 Sep;113(3):570-6.
PMID 20683253
 
Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae.
Brisson L, Gillet L, Calaghan S, Besson P, Le Guennec JY, Roger S, Gore J.
Oncogene. 2011 Apr 28;30(17):2070-6. Epub 2010 Dec 20.
PMID 21170089
 
Written2011-05Zehua Wang
of Obstetrics, Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science, Technology, Wuhan, 430022 China

Citation

This paper should be referenced as such :
Wang, Z
Voltage-Gated Sodium Channel expression, cancer
Atlas Genet Cytogenet Oncol Haematol. 2011;15(10):892-896.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Deep/VGSCandCancerID20096.htm

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 18 17:22:29 CEST 2017


Home   Genes    Leukemias    Solid Tumors    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.